CD274 and diabetes mellitus: ICI-induced diabetes (ICI-DM), primarily observed with anti-PD-1 or anti-PD-L1 therapies, affects approximately 0.2%–1.9% of patients treated with ICIs, but some series with more aggressive ICI regimens have reported up to 11% developing hyperglycemia (1, 2).